<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278304</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454997</org_study_id>
    <secondary_id>NCI-05-C-0233</secondary_id>
    <nct_id>NCT00278304</nct_id>
    <nct_alias>NCT00214396</nct_alias>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Cervical Cancer</brief_title>
  <official_title>A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation&#xD;
      uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving&#xD;
      radiation therapy in different ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving external-beam radiation together&#xD;
      with internal radiation works in treating patients with cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of magnetic resonance-guided, endocavitary, high-dose rate&#xD;
           brachytherapy implants in patients with stage IB-IVB cervical cancer.&#xD;
&#xD;
        -  Provide more reliable dose-volume estimations based on three-dimensional imaging-based&#xD;
           treatment planning in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxic effects and treatment tolerance in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Correlate three-dimensional dose-volume histograms of organs at risk with treatment&#xD;
           toxicity in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the disease status, time and patterns of relapse, and survival of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo external beam radiotherapy 4-5 days a week for up to 7 weeks.&#xD;
      Patients also undergo MRI-guided high-dose brachytherapy comprising one brachytherapy implant&#xD;
      a week for 3-6 implants. Brachytherapy may be administered during or after external beam&#xD;
      radiotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of dose-volume estimations based on 3D imaging-based treatment planning, with the traditional point dose method based on orthogonal radiographs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate three-dimensional dose-volume histograms of organs at risk with treatment toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and patterns of relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival distributions</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the cervix of 1 of the following cellular&#xD;
             subtypes:&#xD;
&#xD;
               -  Squamous cell&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Adenosquamous cell&#xD;
&#xD;
          -  Stages IB-IVA disease&#xD;
&#xD;
               -  Stage IVB disease allowed provided the impact on the quality of life is&#xD;
                  tremendous (e.g., &quot;frozen pelvis&quot; or massive pelvic disease and fistula&#xD;
                  formation, severe pain, or bleeding)&#xD;
&#xD;
          -  Measurable and/or evaluable disease on MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No physical or physiological capacity that would preclude study treatment&#xD;
&#xD;
          -  No cognitively impaired patients who cannot provide informed consent&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No contraindication to MRI, including any of the following:&#xD;
&#xD;
               -  Weight &gt; 136 kg&#xD;
&#xD;
               -  Allergy to MR contrast agent&#xD;
&#xD;
               -  Pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic&#xD;
                  devices&#xD;
&#xD;
          -  No significant unrelated systemic illness&#xD;
&#xD;
          -  No serious infections&#xD;
&#xD;
          -  No significant cardiac, pulmonary, hepatic, or other organ dysfunction that would&#xD;
             preclude study treatment&#xD;
&#xD;
          -  Must be medically fit to receive anesthesia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior definitive brachytherapy procedures&#xD;
&#xD;
               -  Ring implants or intravaginal cones for the relief of excessive bleeding allowed&#xD;
&#xD;
          -  No prior definitive surgical oncologic procedures (e.g., radical hysterectomy)&#xD;
&#xD;
          -  Concurrent chemotherapy, immunotherapy, or hormonal therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shervin Karimpour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Radiation Oncology Branch; ROB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

